No abstract was published with this document — society guidelines, consensus pathways, and scientific statements are typically released without one. See the Key Points and the linked PDF for the full content.
“Our thinking about this disease has evolved. We now better understand the interplay of risk factors involved in both the progression of the disease and the occurrence of adverse events such as heart attack and cardiac death. With this new guideline, we have transitioned from arbitrarily picking and choosing individual therapies to recognizing there is a package of lifestyle modifications and medications—what we call guideline-directed medical therapy—that benefits most patients.”
Fihn et al. (2012) studied this question.